Olutasidenib

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameOlutasidenib
Drug Alias NameIDH1-R132 Inhibitor FT-2102RezlidhiaFT-2102
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIsocitrate dehydrogenase [NADP] cytoplasmic inhibitors
TargetsIsocitrate dehydrogenase [NADP] cytoplasmic
Therapy Area/IndicationsDiarrheaMyelodysplastic SyndromesIrritable Bowel Syndrome +[8] 
Global Approved IndicationsLeukemia, Myeloid, Acute
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/12/01
Country/TerritoryCanadaUnited StatesItaly +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesForma Therapeutics Holdings Inc
China Registration ClassN/A

Develop Information

Active CompaniesForma Therapeutics Holdings IncOrient Europharma Co LtdNational Cancer Institute +[6] 
Inactive CompaniesRigel PharmaceuticalsVirginia Commonwealth University
Active IndicationsDiarrheaMyelodysplastic SyndromesIrritable Bowel Syndrome +[7] 
Inactive IndicationsLeukemia, Promyelocytic, Acute

Other Information

ATC CodeL01XX
Related LinksWikipediaDrugBankKEGG